Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.
Frontiers in immunology（2018）
摘要
[This corrects the article DOI: 10.3389/fimmu.2018.01355.].
更多查看译文
关键词
anti-GD2 chimeric antibody,cytokine biomarkers,cytokines,immunotherapy,neuroblastoma,safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要